|
1
|
GBD 2016 Multiple Sclerosis Collaborators:
Global, regional, and national burden of multiple sclerosis
1990-2016: A systematic analysis for the global burden of disease
study 2016. Lancet Neurol 18: 269-285, 2019.
|
|
2
|
Malpass K: Multiple sclerosis:
‘Outside-in’ demyelination in MS. Nat Rev Neurol.
8(61)2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Traugott U, Reinherz EL and Raine CS:
Multiple sclerosis. Distribution of T cells, T cell subsets and
Ia-positive macrophages in lesions of different ages. J
Neuroimmunol. 4:201–221. 1983.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Lublin FD, Baier M and Cutter G: Effect of
relapses on development of residual deficit in multiple sclerosis.
Neurology. 61:1528–1532. 2003.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Baecher-Allan C, Kaskow BJ and Weiner HL:
Multiple sclerosis: Mechanisms and immunotherapy. Neuron.
97:742–768. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Krone B, Oeffner F and Grange JM: Is the
risk of multiple sclerosis related to the ‘biography’ of the immune
system? J Neurol. 256:1052–1060. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Buljevac D, Flach HZ, Hop WC, Hijdra D,
Laman JD, Savelkoul HF, Van der Maché FG, Van Doorn PA and Hintzen
RQ: Prospective study on the relationship between infections and
multiple sclerosis exacerbations. Brain. 125:952–960.
2002.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Correale J, Fiol M and Gilmore W: The risk
of relapses in multiple sclerosis during systemic infections.
Neurology. 67:652–659. 2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sotelo J, Martínez-Palomo A, Ordoñez G and
Pineda B: Varicella-zoster virus in cerebrospinal fluid at relapses
of multiple sclerosis. Ann Neurol. 63:303–311. 2008.PubMed/NCBI View Article : Google Scholar
|
|
10
|
De Keyser J, Zwanikken C and Boon M:
Effects of influenza vaccination and influenza illness on
exacerbations in multiple sclerosis. J Neurol Sci. 159:51–53.
1998.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Marrie RA, Elliott L, Marriott J, Cossoy
M, Blanchard J, Tennakoon A and Yu N: Dramatically changing rates
and reasons for hospitalization in multiple sclerosis. Neurology.
83:929–937. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Loebermann M, Winkelmann A, Hartung HP,
Hengel H, Reisinger EC and Zettl UK: Vaccination against infection
in patients with multiple sclerosis. Nat Rev Neurol. 8:143–151.
2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Williamson EM and Berger JR: Infection
risk in patients on multiple sclerosis therapeutics. CNS Drugs.
29:229–244. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Geier DA and Geier MR: A case-control
study of serious autoimmune adverse events following hepatitis B
immunization. Autoimmunity. 38:295–301. 2005.PubMed/NCBI View Article : Google Scholar
|
|
15
|
MacLennan IC, Toellner KM, Cunningham AF,
Serre K, Sze DM, Zúñiga E, Cook MC and Vinuesa CG: Extrafollicular
antibody responses. Immunol Rev. 194:8–18. 2003.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zrzavy T, Kollaritsch H, Rommer PS,
Boxberger N, Loebermann M, Wimmer I, Winkelmann A and Zettl UK:
Vaccination in multiple sclerosis: Friend or foe? Front Immunol.
10(1883)2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Plotkin S: History of vaccination. Proc
Natl Acad Sci USA. 111:12283–12287. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Luca S and Mihaescu T: History of BCG
vaccine. Maedica (Buchar). 8:53–58. 2013.PubMed/NCBI
|
|
19
|
Farez MF, Correale J, Armstrong MJ,
Rae-Grant A, Gloss D, Donley D, Holler-Managan Y, Kachuck NJ,
Jeffery D, Beilman M, et al: Practice guideline update summary:
Vaccine-preventable infections and immunization in multiple
sclerosis: Report of the guideline development, dissemination, and
implementation subcommittee of the American academy of neurology.
Neurology. 93:584–594. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Greenwood B: The contribution of
vaccination to global health: Past, present and future. Philos
Trans R Soc Lond B Biol Sci. 369(20130433)2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Geeraedts F, Goutagny N, Hornung V, Severa
M, De Haan A, Pool J, Wilschut J, Fitzgerald KA and Huckriede A:
Superior immunogenicity of inactivated whole virus H5N1 influenza
vaccine is primarily controlled by Toll-like receptor signalling.
PLoS Pathog. 4(e1000138)2008.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Bennett B, Check IJ, Olsen MR and Hunter
RL: A comparison of commercially available adjuvants for use in
research. J Immunol Methods. 153:31–40. 1992.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lindblad EB: Aluminium compounds for use
in vaccines. Immunol Cell Biol. 82:497–505. 2004.PubMed/NCBI View Article : Google Scholar
|
|
24
|
van der Laan JW, Gould S and Tanir JY:
ILSI HESI Vaccines and Adjuvants Safety Project Committee: Safety
of vaccine adjuvants: Focus on autoimmunity. Vaccine. 33:1507–1514.
2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sirbu CA, Sirbu OM, Constantin C and Sandu
A: Neuroimmunotoxicity of aluminum. Farmacia. 63:8–10. 2015.
|
|
26
|
Franceschini F, Bottau P, Caimmi S,
Crisafulli G, Lucia L, Peroni D, Saretta F, Vernich M, Povesi
Dascola C and Caffarelli C: Vaccination in children with allergy to
non active vaccine components. Clin Transl Med. 4(3)2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Lebrun C and Vukusic S: French Group for
Recommendations in Multiple Sclerosis (France4MS) and the Société
Francophone de la Sclérose En Plaques (SFSEP): Immunization and
multiple sclerosis: Recommendations from the French multiple
sclerosis society. Mult Scler Relat Disord. 31:173–188.
2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Fujinami RS and Oldstone MBA: Amino acid
homology between the encephalitogenic site of myelin basic protein
and virus: Mechanism for autoimmunity. Science. 230:1043–1045.
1985.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Hernán MA, Jick SS, Olek MJ and Jick H:
Recombinant hepatitis B vaccine and the risk of multiple sclerosis:
A prospective study. Neurology. 63:838–842. 2004.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Le Houézec D: Evolution of multiple
sclerosis in France since the beginning of hepatitis B vaccination.
Immunol Res. 60:219–225. 2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Elwood JM and Ameratunga R: Autoimmune
diseases after hepatitis B immunization in adults: Literature
review and meta-analysis, with reference to
‘autoimmune/autoinflammatory syndrome induced by adjuvants’ (ASIA).
Vaccine. 36:5796–5802. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Segal Y and Shoenfeld Y: Vaccine-induced
autoimmunity: The role of molecular mimicry and immune
crossreaction. Cell Mol Immunol. 15:586–594. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Scheller NM, Svanström H, Pasternak B,
Arnheim-Dahlström L, Sundström K, Fink K and Hviid A: Quadrivalent
HPV vaccination and risk of multiple sclerosis and other
demyelinating diseases of the central nervous system. JAMA.
313:54–61. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Kurtzke JF, Hyllested K, Arbuckle JD,
Brønnum-Hansen H, Wallin MT, Heltberg A, Jacobsen H, Olsen A and
Eriksen LS: Multiple sclerosis in the Faroe Islands. 7. Results of
a case control questionnaire with multiple controls. Acta Neurol
Scand. 96:149–157. 1997.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ristori G, Romano S, Cannoni S, Visconti
A, Tinelli E, Mendozzi L, Cecconi P, Lanzillo R, Quarantelli M,
Buttinelli C, et al: Effects of Bacille Calmette-Guerin after the
first demyelinating event in the CNS. Neurology. 82:41–48.
2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ristori G, Faustman D, Matarese G, Romano
S and Salvetti M: Bridging the gap between vaccination with Bacille
Calmette-Guérin (BCG) and immunological tolerance: The cases of
type 1 diabetes and multiple sclerosis. Curr Opin Immunol.
55:89–96. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Confavreux C, Suissa S, Saddier P, Bourdès
V and Vukusic S: Vaccines in Multiple Sclerosis Study Group:
Vaccinations and the risk of relapse in multiple sclerosis.
Vaccines in multiple sclerosis study group. N Engl J Med.
344:319–326. 2001.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Moriabadi NF, Niewiesk S, Kruse N, Jung S,
Weissbrich B, ter Meulen V, Toyka KV and Rieckmann P: Influenza
vaccination in MS: Absence of T-cell response against white matter
proteins. Neurology. 56:938–943. 2001.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Hapfelmeier A, Gasperi C, Donnachie E and
Hemmer B: A large case-control study on vaccination as risk factor
for multiple sclerosis. Neurology. 93:e908–e916. 2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Nakajima H, Ohtsuka S, Nishina T, Sugino
M, Kimura F, Hanafusa T, Ikemoto T and Shimizu A: Multiple
sclerosis after allergen-specific immunotherapy and influenza
vaccination. Eur Neurol. 50:248–249. 2003.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Isai A, Durand J, Le Meur S, Hidalgo-Simon
A and Kurz X: Autoimmune disorders after immunisation with
Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance
data and literature review. Vaccine. 30:7123–7129. 2012.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Langer-Gould A, Qian L, Tartof SY, Brara
SM, Jacobsen SJ, Beaber BE, Sy LS, Chao C, Hechter R and Tseng HF:
Vaccines and the risk of multiple sclerosis and other central
nervous system demyelinating diseases. JAMA Neurol. 71:1506–1513.
2014.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Mailand MT and Frederiksen JL: Vaccines
and multiple sclerosis: A systematic review. J Neurol.
264:1035–1050. 2017.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Farez MF and Correale J: Yellow fever
vaccination and increased relapse rate in travelers with multiple
sclerosis. Arch Neurol. 68:1267–1271. 2011.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Morel J, Czitrom SG, Mallick A, Sellam J
and Sibilia J: Vaccinations in adults with chronic inflammatory
joint disease: Immunization schedule and recommendations for
patients taking synthetic or biological disease-modifying
antirheumatic drugs. Joint Bone Spine. 83:135–141. 2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Dargahi N, Katsara M, Tselios T,
Androutsou ME, de Courten M, Matsoukas J and Apostolopoulos V:
Multiple sclerosis: Immunopathology and treatment update. Brain
Sci. 7(78)2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Neuhaus O, Farina C, Wekerle H and
Hohlfeld R: Mechanisms of action of glatiramer acetate in multiple
sclerosis. Neurology. 56:702–708. 2001.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Moharregh-Khiabani D, Linker RA, Gold R
and Stangel M: Fumaric Acid and its esters: An emerging treatment
for multiple sclerosis. Curr Neuropharmacol. 7:60–64.
2009.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Korn T, Magnus T, Toyka K and Jung S:
Modulation of effector cell functions in experimental autoimmune
encephalomyelitis by leflunomide-mechanisms independent of
pyrimidine depletion. J Leukoc Biol. 76:950–960. 2004.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Matloubian M, Lo CG, Cinamon G, Lesneski
MJ, Xu Y, Brinkmann V, Allende ML, Proia RL and Cyster JG:
Lymphocyte egress from thymus and peripheral lymphoid organs is
dependent on S1P receptor 1. Nature. 427:355–360. 2004.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Lenk H, Müller U and Tanneberger S:
Mitoxantrone: Mechanism of action, antitumor activity,
pharmacokinetics, efficacy in the treatment of solid tumors and
lymphomas, and toxicity. Anticancer Res. 7:1257–1264.
1987.PubMed/NCBI
|
|
52
|
Montalban X, Hauser SL, Kappos L, Arnold
DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer
B, et al: Ocrelizumab versus placebo in primary progressive
multiple sclerosis. N Engl J Med. 376:209–220. 2017.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Sirbu CA, Furdu-Lungut E, Plesa CF,
Nicolae AC and Drăgoi CM: Pharmacological treatment of relapsing
remitting multiple sclerosis - where are we? Farmacia. 64:651–656.
2016.
|
|
54
|
Ratchford JN, Costello K, Reich DS and
Calabresi PA: Varicella-zoster virus encephalitis and vasculopathy
in a patient treated with fingolimod. Neurology. 79:2002–2004.
2012.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Sîrbu CA, Drăgoi CM, Nicolae AC and Pleșa
FC: History of interferon treatments in multiple sclerosis - 60
years of progress. Farmacia. 65:14–18. 2017.
|
|
56
|
Fine P, Eames K and Heymann DL: ‘Herd
immunity’: A rough guide. Clin Infect Dis. 52:911–916.
2011.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Triplett J, Kermode AG, Corbett A and
Reddel SW: Warts and all: Fingolimod and unusual HPV-associated
lesions. Mult Scler. 25:1547–1550. 2019.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Kappos L, Mehling M, Arroyo R, Izquierdo
G, Selmaj K, Curovic-Perisic V, Keil A, Bijarnia M, Singh A and von
Rosenstiel P: Randomized trial of vaccination in fingolimod-treated
patients with multiple sclerosis. Neurology. 84:872–879.
2015.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Bar-Or A, Freedman MS, Kremenchutzky M,
Menguy-Vacheron F, Bauer D, Jodl S, Truffinet P, Benamor M,
Chambers S and O'Connor PW: Teriflunomide effect on immune response
to influenza vaccine in patients with multiple sclerosis.
Neurology. 81:552–558. 2013.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Waubant E, Giovannoni G, Hawkes C and Levy
M: Vaccines and disease-modifying treatments. Mult Scler Relat
Disord. 26:A1–A2. 2018.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Olberg HK, Cox RJ, Nostbakken JK, Aarseth
JH, Vedeler CA and Myhr KM: Immunotherapies influence the influenza
vaccination response in multiple sclerosis patients: An explorative
study. Mult Scler. 20:1074–1080. 2014.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Shirani A, Zhao Y, Karim ME, Evans C,
Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J and
Tremlett H: Association between use of interferon beta and
progression of disability in patients with relapsing-remitting
multiple sclerosis. JAMA. 308:247–256. 2012.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Olberg HK, Eide GE, Cox RJ, Jul-Larsen Å,
Lartey SL, Vedeler CA and Myhr KM: Antibody response to seasonal
influenza vaccination in patients with multiple sclerosis receiving
immunomodulatory therapy. Eur J Neurol. 25:527–534. 2018.PubMed/NCBI View Article : Google Scholar
|
